LLYC Stock Financial Analysis - Eli Lilly and Company (WBAG) Stock

Overview

Eli Lilly and Company, headquartered in Indianapolis, Indiana, USA, operates as a global pharmaceutical leader primarily focused on the discovery, development, and marketing of pharmaceutical products. The company specializes in a broad range of therapeutic areas including diabetes, oncology, immunology, and neurology. Key projects of Eli Lilly involve the development of innovative treatments for complex diseases such as Alzheimer’s through their drug Donanemab, and diabetes with drugs like Mounjaro (tirzepatide). Additionally, their robust research and development efforts emphasize advancing a pipeline that addresses unmet medical needs, a strategy supported by substantial investments in both technology and strategic collaborations within the biotech and pharmaceutical sectors. This focus underscores Eli Lilly's commitment to innovation and its role in shaping the future of healthcare.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Eli Lilly and Company as of 30 June 2025 is 53,258.10 MM.
The operating income for Eli Lilly and Company as of 30 June 2025 is 22,882.20 MM.
The net income for Eli Lilly and Company as of 30 June 2025 is 13,799.90 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	53,258.10	22,882.20	13,799.90
2025-03-31	49,003.20	20,174.50	11,106.40
2024-12-31	45,042.70	17,501.70	10,590.00
2024-09-30	40,863.30	14,897.00	8,369.90
2024-06-30	38,922.80	13,888.20	7,342.20
2024-03-31	35,932.10	11,808.10	6,138.40
2023-12-31	34,124.10	10,787.30	5,240.40
2023-09-30	32,072.50	9,801.70	4,988.40
2023-06-30	29,515.50	8,298.50	6,497.50
2023-03-31	27,691.40	7,704.90	5,686.80
2022-12-31	28,541.40	8,653.30	6,244.80
2022-09-30	29,239.50	8,882.40	6,033.20
2022-06-30	29,070.70	8,906.60	5,691.60
2022-03-31	29,322.80	9,183.60	6,129.30
2021-12-31	28,318.40	8,272.70	5,581.70
2021-09-30	27,758.50	8,221.70	5,972.40
2021-06-30	26,726.30	7,653.40	6,070.70
2021-03-31	25,485.60	7,106.10	6,092.50
2020-12-31	24,539.80	7,210.80	6,193.70
2020-09-30	23,213.80	6,319.70	5,572.60
2020-06-30

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31	11.76	11.71
2024-09-30	9.29	9.25
2024-06-30	8.15	8.12
2024-03-31	6.82	6.79
2023-12-31	5.82	5.80
2023-09-30	5.54	5.52
2023-06-30	7.21	7.18
2023-03-31	6.31	6.29
2022-12-31	6.93	6.90
2022-09-30	6.68	6.65
2022-06-30	6.30	6.27
2022-03-31	6.77	6.73
2021-12-31	6.15	6.12
2021-09-30	6.58	6.55
2021-06-30	6.69	6.65
2021-03-31	6.71	6.68
2020-12-31	6.82	6.79
2020-09-30	6.14	6.11
2020-06-30	6.18	6.15

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Eli Lilly and Company as of 30 June 2025 is 10,938.20 MM.
The cash from investing activities for Eli Lilly and Company as of 30 June 2025 is -11,112.40 MM.
The cash from financing activities for Eli Lilly and Company as of 30 June 2025 is 120.70 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	10,938.20	-11,112.40	120.70
2025-03-31	9,317.50	-11,476.20	2,921.10
2024-12-31	8,817.90	-9,301.50	1,230.10
2024-09-30	6,032.20	-10,305.30	5,000.20
2024-06-30	4,509.80	-9,381.10	5,360.90
2024-03-31	3,675.50	-7,641.50	2,772.00
2023-12-31	4,240.10	-7,152.70	3,495.60
2023-09-30	6,214.70	-5,171.90	-1,190.50
2023-06-30	6,241.90	-3,046.70	-3,025.80
2023-03-31	6,793.30	-3,414.10	-2,116.10
2022-12-31	7,585.70	-3,762.90	-5,406.70
2022-09-30	8,079.50	-3,198.40	-5,791.80
2022-06-30	7,494.10	-2,859.60	-4,991.70
2022-03-31	8,086.30	-2,516.40	-5,951.20
2021-12-31	7,365.90	-2,867.50	-4,131.30
2021-09-30	6,919.40	-3,057.40	-3,896.30
2021-06-30	7,094.70	-2,754.40	-3,712.20
2021-03-31	7,814.60	-2,481.50	-4,302.20
2020-12-31	6,499.60	-2,258.90	-3,137.10
2020-09-30	6,648.10	-1,626.20	-2,959.20
2020-06-30

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30

Management Effectiveness

The roa for Eli Lilly and Company as of 30 June 2025 is 0.15.
The roe for Eli Lilly and Company as of 30 June 2025 is 0.81.
The roic for Eli Lilly and Company as of 30 June 2025 is 0.20.
The croic for Eli Lilly and Company as of 30 June 2025 is 0.01.
The ocroic for Eli Lilly and Company as of 30 June 2025 is 0.17.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	0.15	0.81	0.20	0.01	0.17
2025-03-31	0.17	0.82	0.21	0.01	0.17
2024-12-31	0.13	0.94	0.18	0.02	0.13
2024-09-30	0.13	0.74	0.17	0.01	0.11
2024-06-30	0.12	0.54	0.15	-0.03	0.09
2024-03-31	0.11	0.52	0.14	0.02	0.11
2023-12-31	0.11	0.49	0.16	-0.01	0.18
2023-09-30	0.14	0.75	0.22	0.00	0.19
2023-06-30	0.12	0.75	0.21	0.00	0.19
2023-03-31	0.13	0.62	0.20	0.04	0.22
2022-12-31	0.13	0.91	0.23	-0.04	0.29
2022-09-30	0.12	0.91	0.22	-0.04	0.28
2022-06-30	0.13	0.85	0.22	-0.02	0.27
2022-03-31	0.12	0.86	0.23	-0.02	0.30
2021-12-31	0.13	0.96	0.21	0.01	0.29
2021-09-30	0.14	1.20	0.26	0.01	0.30
2021-06-30	0.14	1.42	0.27	0.04	0.32
2021-03-31	0.15	2.26	0.25	0.05	0.33
2020-12-31	0.16	1.79	0.27	0.06	0.28
2020-09-30	0.15	1.95	0.26	0.09	0.31
2020-06-30	0.15	2.19	0.28	0.00	0.31

Gross Margins

The gross margin for Eli Lilly and Company as of 30 June 2025 is 0.82.
The net margin for Eli Lilly and Company as of 30 June 2025 is 0.23.
The operating margin for Eli Lilly and Company as of 30 June 2025 is 0.41.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.82	0.23	0.41
2025-03-31	0.81	0.24	0.38
2024-12-31	0.81	0.20	0.37
2024-09-30	0.81	0.19	0.36
2024-06-30	0.80	0.17	0.33
2024-03-31	0.79	0.15	0.30
2023-12-31	0.79	0.16	0.31
2023-09-30	0.78	0.22	0.29
2023-06-30	0.78	0.22	0.29
2023-03-31	0.77	0.21	0.28
2022-12-31	0.75	0.21	0.31
2022-09-30	0.75	0.21	0.31
2022-06-30	0.75	0.20	0.31
2022-03-31	0.74	0.21	0.31
2021-12-31	0.76	0.20	0.27
2021-09-30	0.76	0.22	0.29
2021-06-30	0.76	0.23	0.29
2021-03-31	0.76	0.24	0.28
2020-12-31	0.78	0.25	0.28
2020-09-30	0.78	0.24	0.27
2020-06-30	0.79	0.24	0.28

IT:1LLY	€ 620,40
CH:LLY
GB:0Q1G
GB:LLYZ
DE:LLY	€ 620,20
BG:LLY
MX:LLY
CL:LLY
US:LLY	US$ 727,21
PE:LLY
GB:LLYD
CL:LLYCL